Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07).

Publication

Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07).

Journal Paper/Review - Feb 19, 2018

Beier Dagmar, Proescholdt Martin, Reinert Christiane, Pietsch Torsten, Jones David T W, Pfister Stefan M, Hattingen Elke, Seidel Clemens, Dirven Linda, Luerding Ralf, Reijneveld Jaap, Warmuth-Metz Monika, Bonsanto Matteo, Bremer Michael, Combs Stephanie E, Rieken Stefan, Herrlinger Ulrich, Kuntze Holger, Mayer-Steinacker Regine, Moskopp Dag, Schneider Thomas, Beringer Andreas, Schlegel Uwe, Stummer Walter, Welker Helmut, Weyerbrock Astrid, Paulsen Frank, Rutkowski Stefan, Weller Michael, Wick Wolfgang, Kortmann Rolf-Dieter, Bogdahn Ulrich, Hau Peter

Citation

Beier D, Proescholdt M, Reinert C, Pietsch T, Jones D, Pfister S, Hattingen E, Seidel C, Dirven L, Luerding R, Reijneveld J, Warmuth-Metz M, Bonsanto M, Bremer M, Combs S, Rieken S, Herrlinger U, Kuntze H, Mayer-Steinacker R, Moskopp D, Schneider T, Beringer A, Schlegel U, Stummer W, Welker H, Weyerbrock A, Paulsen F, Rutkowski S, Weller M, Wick W, Kortmann R, Bogdahn U, Hau P. Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). Neuro Oncol 2018; 20:400-410.

Type

Journal Paper/Review (English)

Journal

Neuro Oncol 2018; 20

Publication Date

Feb 19, 2018

Issn Electronic

1523-5866

Pages

400-410

Brief description/objective

Medulloblastoma in adult patients is rare, with 0.6 cases per million. Prognosis depends on clinical factors and medulloblastoma entity. No prospective data on the feasibility of radiochemotherapy exist. The German Neuro-Oncology Working Group (NOA) performed a prospective descriptive multicenter single-arm phase II trial to evaluate feasibility and toxicity of radio-polychemotherapy.